Search

Your search keyword '"Battaglin, Francesca"' showing total 437 results
Start Over Author "Battaglin, Francesca"
437 results on '"Battaglin, Francesca"'

151. AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta‐analysis using TRIBE, MAVERICC and FIRE3

Author

Tokunaga, Ryuma, primary, Cao, Shu, additional, Naseem, Madiha, additional, Battaglin, Francesca, additional, Lo, Jae Ho, additional, Arai, Hiroyuki, additional, Loupakis, Fotios, additional, Stintzing, Sebastian, additional, Puccini, Alberto, additional, Berger, Martin D, additional, Soni, Shivani, additional, Zhang, Wu, additional, Mancao, Christoph, additional, Salhia, Bodour, additional, Mumenthaler, Shannon M, additional, Weisenberger, Daniel J., additional, Liang, Gangning, additional, Cremolini, Chiara, additional, Heinemann, Volker, additional, Falcone, Alfredo, additional, Millstein, Joshua, additional, and Lenz, Heinz‐Josef, additional

Published
2019
Full Text
View/download PDF

152. Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy

Author

Tokunaga, Ryuma, primary, Cao, Shu, additional, Naseem, Madiha, additional, Lo, Jae Ho, additional, Battaglin, Francesca, additional, Puccini, Alberto, additional, Berger, Martin D., additional, Soni, Shivani, additional, Millstein, Joshua, additional, Zhang, Wu, additional, Stintzing, Sebastian, additional, Loupakis, Fotios, additional, Cremolini, Chiara, additional, Heinemann, Volker, additional, Falcone, Alfredo, additional, and Lenz, Heinz-Josef, additional

Published
2019
Full Text
View/download PDF

153. Th17 cell pathway-related genetic variants in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC, and FIRE-3.

Author

Tokunaga, Ryuma, primary, Cao, Shu, additional, Battaglin, Francesca, additional, Lo, Jae Ho, additional, Loupakis, Fotios, additional, Stintzing, Sebastian, additional, Naseem, Madiha, additional, Puccini, Alberto, additional, Berger, Martin D., additional, Zhang, Wu, additional, Mancao, Christoph, additional, Salhia, Bodour, additional, Mumenthaler, Shannon M, additional, Weisenberger, Daniel J, additional, Liang, Gangning, additional, Cremolini, Chiara, additional, Heinemann, Volker, additional, Falcone, Alfredo, additional, Millstein, Joshua, additional, and Lenz, Heinz-Josef, additional

Published
2019
Full Text
View/download PDF

154. Comprehensive molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon.

Author

Puccini, Alberto, primary, Poorman, Kelsey, additional, Salem, Mohamed E., additional, Goldberg, Richard M., additional, Shields, Anthony Frank, additional, Berger, Martin D, additional, Battaglin, Francesca, additional, Tokunaga, Ryuma, additional, Naseem, Madiha, additional, Zhang, Wu, additional, Soni, Shivani, additional, Korn, W. Michael, additional, Philip, Philip Agop, additional, Marshall, John, additional, and Lenz, Heinz-Josef, additional

Published
2019
Full Text
View/download PDF

155. Polymorphisms in the telomerase complex to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.

Author

Battaglin, Francesca, primary, Loupakis, Fotios, additional, Stintzing, Sebastian, additional, Cao, Shu, additional, Puccini, Alberto, additional, Tokunaga, Ryuma, additional, Naseem, Madiha, additional, Berger, Martin D., additional, Soni, Shivani, additional, Lo, Jae Ho, additional, Bergamo, Francesca, additional, Lonardi, Sara, additional, Millstein, Joshua, additional, Zhang, Wu, additional, Zagonel, Vittorina, additional, Cremolini, Chiara, additional, Falcone, Alfredo, additional, Heinemann, Volker, additional, and Lenz, Heinz-Josef, additional

Published
2019
Full Text
View/download PDF

156. Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE.

Author

Berger, Martin D., primary, Stintzing, Sebastian, additional, Heinemann, Volker, additional, Cao, Shu, additional, Miyamoto, Yuji, additional, Suenaga, Mitsukuni, additional, Hanna, Diana L., additional, Soni, Shivani, additional, Puccini, Alberto, additional, Tokunaga, Ryuma, additional, Naseem, Madiha, additional, Battaglin, Francesca, additional, Zhang, Wu, additional, Cremolini, Chiara, additional, Falcone, Alfredo, additional, Loupakis, Fotios, additional, and Lenz, Heinz-Josef, additional

Published
2019
Full Text
View/download PDF

157. Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.

Author

Battaglin, Francesca, primary, Puccini, Alberto, additional, Cao, Shu, additional, Millstein, Joshua, additional, Tokunaga, Ryuma, additional, Naseem, Madiha, additional, Soni, Shivani, additional, Lo, Jae Ho, additional, Ning, Tricia, additional, Arai, Hiroyuki, additional, Berger, Martin D., additional, Barzi, Afsaneh, additional, Zhang, Wu, additional, Heinemann, Volker, additional, Stintzing, Sebastian, additional, and Lenz, Heinz-Josef, additional

Published
2019
Full Text
View/download PDF

158. B cell and B cell-related pathways for novel cancer treatments

Author

Tokunaga, Ryuma, primary, Naseem, Madiha, additional, Lo, Jae Ho, additional, Battaglin, Francesca, additional, Soni, Shivani, additional, Puccini, Alberto, additional, Berger, Martin D., additional, Zhang, Wu, additional, Baba, Hideo, additional, and Lenz, Heinz-Josef, additional

Published
2019
Full Text
View/download PDF

159. Characteristics of colorectal cancer (CRC) patients with BRCA1 and BRCA2 mutations.

Author

Naseem, Madiha, primary, Xiu, Joanne, additional, Salem, Mohamed E., additional, Goldberg, Richard M., additional, Vanderwalde, Ari M., additional, Grothey, Axel, additional, Philip, Philip Agop, additional, Seeber, Andreas, additional, Puccini, Alberto, additional, Tokunaga, Ryuma, additional, Battaglin, Francesca, additional, Berger, Martin D., additional, Barzi, Afsaneh, additional, Hanna, Diana L., additional, Zhang, Wu, additional, Hwang, Jimmy J., additional, Shields, Anthony Frank, additional, Marshall, John, additional, Korn, Wolfgang Michael, additional, and Lenz, Heinz-Josef, additional

Published
2019
Full Text
View/download PDF

161. BMAL1 Links Bevacizumab Resistance in Colorectal Cancer to Circadian Rhythm and Heme Receptor REVERBA

Author

Burgermeister, Elke, primary, Battaglin, Francesca, additional, Eladly, Fagr, additional, Wu, Wen, additional, Herweck, Frank, additional, Schulte, Nadine, additional, Betge, Johannes, additional, Härtel, Nicolai, additional, Kather, Jakob N., additional, Weis, Cleo-Aron, additional, Gaiser, Timo, additional, Marx, Alexander, additional, Weiss, Christel, additional, Hofheinz, Ralf, additional, Miller, Ian S., additional, Loupakis, Fotios, additional, Lenz, Heinz-Josef, additional, Byrne, Annette T., additional, and Ebert, Matthias P., additional

Published
2019
Full Text
View/download PDF

162. Tandem repeat variation near the HIC1 promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer

Author

Okazaki, Satoshi, Schirripa, Marta, Loupakis, Fotios, Cao, Shu, Zhang, Wu, Yang, Dongyun, Ning, Yan, Berger, Martin D., Miyamoto, Yuji, Suenaga, Mitsukuni, Iqubal, Syma, Barzi, Afsaneh, Cremolini, Chiara, Falcone, Alfredo, Battaglin, Francesca, Salvatore, Lisa, Borelli, Beatrice, Helentjaris, Timothy G., and Lenz, Heinz-Josef

Subjects
Adult, Male, Polymorphism, Genetic, Organoplatinum Compounds, Kruppel-Like Transcription Factors, Minisatellite Repeats, Middle Aged, Prognosis, Article, Cohort Studies, Oxaliplatin, Young Adult, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, Female, Neoplasm Metastasis, Colorectal Neoplasms, Promoter Regions, Genetic, Aged
Abstract

The hypermethylated in cancer 1/sirtuin 1 (HIC1/SIRT1) axis plays an important role in regulating the nucleotide excision repair pathway, which is the main oxaliplatin-induced damage-repair system. On the basis of prior evidence that the variable number of tandem repeat (VNTR) sequence located near the promoter lesion of HIC1 is associated with HIC1 gene expression, the authors tested the hypothesis that this VNTR is associated with clinical outcome in patients with metastatic colorectal cancer who receive oxaliplatin-based chemotherapy.Four independent cohorts were tested. Patients who received oxaliplatin-based chemotherapy served as the training cohort (n = 218), and those who received treatment without oxaliplatin served as the control cohort (n = 215). Two cohorts of patients who received oxaliplatin-based chemotherapy were used for validation studies (n = 176 and n = 73). The VNTR sequence near HIC1 was analyzed by polymerase chain reaction analysis and gel electrophoresis and was tested for associations with the response rate, progression-free survival, and overall survival.In the training cohort, patients who harbored at least 5 tandem repeats (TRs) in both alleles had a significantly shorter PFS compared with those who had fewer than 4 TRs in at least 1 allele (9.5 vs 11.6 months; hazard ratio, 1.93; P = .012), and these findings remained statistically significant after multivariate analysis (hazard ratio, 2.00; 95% confidence interval, 1.13-3.54; P = .018). This preliminary association was confirmed in the validation cohort, and patients who had at least 5 TRs in both alleles had a worse PFS compared with the other cohort (7.9 vs 9.8 months; hazard ratio, 1.85; P = .044).The current findings suggest that the VNTR sequence near HIC1 could be a predictive marker for oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Cancer 2017;123:4506-14. © 2017 American Cancer Society.

Published
2017

163. Molecular Analyses of Left‐ and Right‐Sided Tumors in Adolescents and Young Adults with Colorectal Cancer.

Author

Salem, Mohamed E., Battaglin, Francesca, Goldberg, Richard M., Puccini, Alberto, Shields, Anthony F., Arguello, David, Korn, W. Michael, Marshall, John L., Grothey, Axel, and Lenz, Heinz‐Josef

Subjects
CARCINOGENESIS, CANCER patients, CHROMOSOMES, COLON tumors, DNA, GENE amplification, GENE expression, GENES, HISTONES, GENETIC mutation, RECTUM tumors, DISEASE progression, GENE expression profiling, DESCRIPTIVE statistics, SEQUENCE analysis, EPIGENOMICS, ADOLESCENCE, ADULTS
Abstract

Background: The incidence of colorectal cancer (CRC), particularly left‐sided tumors (LT), in adolescents and young adults (AYA) is rising. Epigenetic events appear to play an important role in tumorigenesis and cancer progression, especially in younger patients. We compared molecular features of LT to right‐sided tumors (RT) in AYA. Materials and Methods: A total of 246 LT and 56 RT were identified in a cohort of 612 AYA with primary CRC. Tumors were examined by next‐generation sequencing (NGS), protein expression, and gene amplification. Tumor mutational burden (TMB) and microsatellite instability (MSI) were determined based on NGS data. Results: RT showed higher mutation rates compared with LT in several genes including BRAF (10.3% vs. 2.8%), KRAS (64.1% vs. 45.5%), PIK3CA (27% vs. 11.2%), and RNF43 (24.2% vs. 2.9%). Notably, additional mutations in distinct genes involved in histone modification and chromatin remodeling, as well as genes associated with DNA repair and cancer‐predisposing syndromes, were characteristic of RT; most frequently KMT2D (27.8% vs. 3.4%), ARID1A (53.3% vs. 21.4%), MSH6 (11.1% vs. 2.3%), MLH1 (10.5% vs. 2.3%), MSH2 (10.5% vs. 1.2%), POLE (5.9% vs. 0.6%), PTEN (10.8% vs. 2.3%), and BRCA1 (5.4% vs. 0.6%). MSI was seen in 20.8% of RT versus 4.8% of LT. RT had a higher frequency of TMB‐high regardless of MSI status. Conclusion: Molecular profiling of AYA CRC revealed different molecular characteristics in RT versus LT. Epigenetic mechanisms and alteration in DNA repair genes warrant further investigation and may be a promising treatment target for CRC in AYA. Implications for Practice: Colorectal cancer (CRC) in adolescents and young adults (AYA) comprises a distinct entity with different clinicopathologic features and prognosis compared with older patients. Molecular profiling of right‐ and left‐sided tumors in AYA is needed to gain novel insight into CRC biology and to tailor targeted treatment in this age group. This study found that right‐ and left‐sided CRC show distinct molecular features in AYA, overall and in subgroups based on microsatellite instability status. Alterations in DNA double‐strand break repair and homologous recombination repair, as well as epigenetic mechanisms, appear to play a critical role. The present molecular profiling data may support the development of personalized treatment strategies in the AYA population. This article explores the molecular makeup of left‐sided and right‐sided colorectal cancers in populations aged 40 years. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

164. Partition: a surjective mapping approach for dimensionality reduction.

Author

Millstein, Joshua, Battaglin, Francesca, Barrett, Malcolm, Cao, Shu, Zhang, Wu, Stintzing, Sebastian, Heinemann, Volker, and Lenz, Heinz-Josef

Subjects
*PROGRESSION-free survival, *INTERNET servers, *NONNEGATIVE matrices, *PRINCIPAL components analysis, *MATRIX decomposition, *NOISE control, *COLON cancer
Abstract

Motivation Large amounts of information generated by genomic technologies are accompanied by statistical and computational challenges due to redundancy, badly behaved data and noise. Dimensionality reduction (DR) methods have been developed to mitigate these challenges. However, many approaches are not scalable to large dimensions or result in excessive information loss. Results The proposed approach partitions data into subsets of related features and summarizes each into one and only one new feature, thus defining a surjective mapping. A constraint on information loss determines the size of the reduced dataset. Simulation studies demonstrate that when multiple related features are associated with a response, this approach can substantially increase the number of true associations detected as compared to principal components analysis, non-negative matrix factorization or no DR. This increase in true discoveries is explained both by a reduced multiple-testing challenge and a reduction in extraneous noise. In an application to real data collected from metastatic colorectal cancer tumors, more associations between gene expression features and progression free survival and response to treatment were detected in the reduced than in the full untransformed dataset. Availability and implementation Freely available R package from CRAN, https://cran.r-project.org/package=partition. Supplementary information Supplementary data are available at Bioinformatics online. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

165. Abstract 2614: Macrophage erythroblast attacher (MAEA) polymorphisms are associated with clinical outcome in TRIBE study mCRC patients treated with 5-fluorouracil/bevacizumab-based therapy

Author

Soni, Shivani, primary, Miyamoto, Yuji, additional, Zhang, Wu, additional, Berger, Martin D., additional, Cao, Shu, additional, Melendez, Elizabeth, additional, Puccini, Alberto, additional, Naseem, Madiha, additional, Tokunaga, Ryuma, additional, Battaglin, Francesca, additional, Mcskane, Michelle, additional, Cremolini, Chiara, additional, Falcone, Alfredo, additional, Loupakis, Fotios, additional, and Lenz, Heinz-Josef, additional

Published
2018
Full Text
View/download PDF

167. Comprehensive genomic profiling of 724 gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Author

Puccini, Alberto, primary, Poorman, Kelsey, additional, Salem, Mohamed E., additional, Goldberg, Richard M., additional, Shields, Anthony Frank, additional, Xiu, Joanne, additional, Korn, Wolfgang Michael, additional, Seeber, Andreas, additional, Berger, Martin D., additional, Tokunaga, Ryuma, additional, Naseem, Madiha, additional, Battaglin, Francesca, additional, Barzi, Afsaneh, additional, Iqbal, Syma, additional, Zhang, Wu, additional, Soni, Shivani, additional, Hwang, Jimmy J., additional, Philip, Philip Agop, additional, Marshall, John, additional, and Lenz, Heinz-Josef, additional

Published
2018
Full Text
View/download PDF

168. Circadian clock gene PER1 mutations in colorectal cancer (CRC).

Author

Battaglin, Francesca, primary, Xiu, Joanne, additional, Winerip, Michelle, additional, Goldberg, Richard M., additional, Philip, Philip Agop, additional, Seeber, Andreas, additional, Puccini, Alberto, additional, Tokunaga, Ryuma, additional, Naseem, Madiha, additional, Soni, Shivani, additional, McSkane, Michelle, additional, Berger, Martin D., additional, Barzi, Afsaneh, additional, Zhang, Wu, additional, Hwang, Jimmy J., additional, Shields, Anthony Frank, additional, Marshall, John, additional, Korn, Wolfgang Michael, additional, and Lenz, Heinz-Josef, additional

Published
2018
Full Text
View/download PDF

169. Genetic variations in the β2M/HLA-E immunomodulatory complex to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line FOLFIRI/Cetuximab: Data from the phase III FIRE-3 trial.

Author

Naseem, Madiha, primary, Stintzing, Sebastian, additional, Cao, Shu, additional, Puccini, Alberto, additional, Tokunaga, Ryuma, additional, Battaglin, Francesca, additional, Barzi, Afsaneh, additional, Berger, Martin D., additional, Soni, Shivani, additional, McSkane, Michelle, additional, Zhang, Wu, additional, Millstein, Joshua, additional, Heinemann, Volker, additional, and Lenz, Heinz-Josef, additional

Published
2018
Full Text
View/download PDF

170. Molecular characterization of appendiceal cancer and comparison with right-sided (R-CRC) and left-sided colorectal cancer (L-CRC).

Author

Tokunaga, Ryuma, primary, Xiu, Joanne, additional, Johnston, Curtis, additional, Goldberg, Richard M., additional, Philip, Philip Agop, additional, Seeber, Andreas, additional, Puccini, Alberto, additional, Naseem, Madiha, additional, Battaglin, Francesca, additional, Berger, Martin D., additional, Soni, Shivani, additional, McSkane, Michelle, additional, Barzi, Afsaneh, additional, Zhang, Wu, additional, Hwang, Jimmy J., additional, Shields, Anthony Frank, additional, Marshall, John, additional, Korn, Wolfgang Michael, additional, and Lenz, Heinz-Josef, additional

Published
2018
Full Text
View/download PDF

171. Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.

Author

Battaglin, Francesca, primary, Cao, Shu, additional, Millstein, Joshua, additional, Puccini, Alberto, additional, Tokunaga, Ryuma, additional, Naseem, Madiha, additional, Soni, Shivani, additional, McSkane, Michelle, additional, Berger, Martin D., additional, Barzi, Afsaneh, additional, Zhang, Wu, additional, Zagonel, Vittorina, additional, Cremolini, Chiara, additional, Stintzing, Sebastian, additional, Loupakis, Fotios, additional, Falcone, Alfredo, additional, Heinemann, Volker, additional, and Lenz, Heinz-Josef, additional

Published
2018
Full Text
View/download PDF

172. Genetic variants within the glucocorticoids related genes to predict outcome in patients with metastatic colorectal cancer (mCRC).

Author

Puccini, Alberto, primary, Loupakis, Fotios, additional, Cao, Shu, additional, Tokunaga, Ryuma, additional, Naseem, Madiha, additional, Battaglin, Francesca, additional, Berger, Martin D., additional, McSkane, Michelle, additional, Soni, Shivani, additional, Zhang, Wu, additional, Millstein, Joshua, additional, Mancao, Christoph, additional, Cremolini, Chiara, additional, Falcone, Alfredo, additional, and Lenz, Heinz-Josef, additional

Published
2018
Full Text
View/download PDF

173. The impact of Th17 cell pathway-related genetic variants in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy.

Author

Tokunaga, Ryuma, primary, Cao, Shu, additional, Puccini, Alberto, additional, Naseem, Madiha, additional, Battaglin, Francesca, additional, Barzi, Afsaneh, additional, Millsteinand, Joshua, additional, Soni, Shivani, additional, Berger, Martin D., additional, McSkane, Michelle, additional, Zhang, Wu, additional, Loupakis, Fotios, additional, Cremolini, Chiara, additional, Falcone, Alfredo, additional, and Lenz, Heinz-Josef, additional

Published
2018
Full Text
View/download PDF

174. Outlooks on Epstein-Barr virus associated gastric cancer

Author

Naseem, Madiha, primary, Barzi, Afsaneh, additional, Brezden-Masley, Christine, additional, Puccini, Alberto, additional, Berger, Martin D., additional, Tokunaga, Ryuma, additional, Battaglin, Francesca, additional, Soni, Shivani, additional, McSkane, Michelle, additional, Zhang, Wu, additional, and Lenz, Heinz-Josef, additional

Published
2018
Full Text
View/download PDF

175. NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients

Author

Schirripa, Marta, primary, Zhang, Wu, additional, Yang, Dongyun, additional, Cao, Shu, additional, Okazaki, Satoshi, additional, Loupakis, Fotios, additional, Berger, Martin D., additional, Ning, Yan, additional, Miyamoto, Yuji, additional, Suenaga, Mitsukuni, additional, Alberti, Giulia, additional, West, Jordan D., additional, Lonardi, Sara, additional, Khoukaz, Taline, additional, Bergamo, Francesca, additional, Battaglin, Francesca, additional, Antoniotti, Carlotta, additional, Falcone, Alfredo, additional, Stintzing, Sebastian, additional, Heinemann, Volker, additional, and Lenz, Heinz-Josef, additional

Published
2018
Full Text
View/download PDF

177. The impact of Tfh cell/ B cell pathway-related genetic variants in metastatic colorectal cancer patients with bevacizumab-based chemotherapy.

Author

Tokunaga, Ryuma, primary, Cao, Shu, additional, Zhang, Wu, additional, Puccini, Alberto, additional, Berger, Martin D, additional, Naseem, Madiha, additional, BATTAGLIN, FRANCESCA, additional, Soni, Shivani, additional, McSkane, Michelle, additional, Stintzing, Sebastian, additional, Loupakis, Fotios, additional, Heinemann, Volker, additional, Falcone, Alfredo, additional, Millstein, Joshua, additional, and Lenz, Heinz Josef, additional

Published
2018
Full Text
View/download PDF

178. Polymorphism in cancer-associated fibroblasts (CAFs) related genes and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) enrolled in two independent randomized phase III trials: TRIBE and FIRE-3.

Author

Puccini, Alberto, primary, Berger, Martin D., additional, Tokunaga, Ryuma, additional, Naseem, Madiha, additional, BATTAGLIN, FRANCESCA, additional, Cao, Shu, additional, Millstein, Joshua, additional, Soni, Shivani, additional, McSkane, Michelle, additional, Zhang, Wu, additional, Loupakis, Fotios, additional, Stintzing, Sebastian, additional, Heinemann, Volker, additional, Falcone, Alfredo, additional, and Lenz, Heinz-Josef, additional

Published
2018
Full Text
View/download PDF

179. Polymorphisms in beta-defensin pathways and clinical outcomes in metastatic colorectal cancer patients treated with FOLFIRI-bevacizumab in two randomized phase III trials.

Author

Naseem, Madiha, primary, Berger, Martin D, additional, Puccini, Alberto, additional, Tokunaga, Ryuma, additional, BATTAGLIN, FRANCESCA, additional, Barzi, Afsaneh, additional, Soni, Shivani, additional, McSkane, Michelle, additional, Cao, Shu, additional, Millstein, Joshua, additional, Zhang, Wu, additional, Loupakis, Fotios, additional, Stintzing, Sebastian, additional, Heinemann, Volker, additional, Falcone, Alfredo, additional, and Lenz, Heinz-Josef, additional

Published
2018
Full Text
View/download PDF

180. Genetic variants in methylation and demethylation pathways to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/Bev: Data from TRIBE and FIRE-3 trials.

Author

Puccini, Alberto, primary, Loupakis, Fotios, additional, Stintzing, Sebastian, additional, Berger, Martin D., additional, Tokunaga, Ryuma, additional, Naseem, Madiha, additional, BATTAGLIN, FRANCESCA, additional, Cao, Shu, additional, Millstein, Joshua, additional, Soni, Shivani, additional, McSkane, Michelle, additional, Zhang, Wu, additional, Heinemann, Volker, additional, Falcone, Alfredo, additional, and Lenz, Heinz-Josef, additional

Published
2018
Full Text
View/download PDF

181. Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy

Author

Fanotto, Valentina, primary, Uccello, Mario, additional, Pecora, Irene, additional, Rimassa, Lorenza, additional, Leone, Francesco, additional, Rosati, Gerardo, additional, Santini, Daniele, additional, Giampieri, Riccardo, additional, Di Donato, Samantha, additional, Tomasello, Gianluca, additional, Silvestris, Nicola, additional, Pietrantonio, Filippo, additional, Battaglin, Francesca, additional, Avallone, Antonio, additional, Scartozzi, Mario, additional, Lutrino, Eufemia Stefania, additional, Melisi, Davide, additional, Antonuzzo, Lorenzo, additional, Pellegrino, Antonio, additional, Ferrari, Laura, additional, Bordonaro, Roberto, additional, Vivaldi, Caterina, additional, Gerratana, Lorenzo, additional, Bozzarelli, Silvia, additional, Filippi, Roberto, additional, Bilancia, Domenico, additional, Russano, Marco, additional, and Aprile, Giuseppe, additional

Published
2018
Full Text
View/download PDF

182. The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients

Author

Battaglin, Francesca, primary, Schirripa, Marta, additional, Buggin, Federica, additional, Pietrantonio, Filippo, additional, Morano, Federica, additional, Boscolo, Giorgia, additional, Tonini, Giuseppe, additional, Lutrino, Eufemia Stefania, additional, Lucchetti, Jessica, additional, Salvatore, Lisa, additional, Passardi, Alessandro, additional, Cremolini, Chiara, additional, Arnoldi, Ermenegildo, additional, Scartozzi, Mario, additional, Pella, Nicoletta, additional, Boni, Luca, additional, Bergamo, Francesca, additional, Zagonel, Vittorina, additional, Loupakis, Fotios, additional, and Lonardi, Sara, additional

Published
2018
Full Text
View/download PDF

185. Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy

Author

Fanotto, Valentina, primary, Uccello, Mario, additional, Pecora, Irene, additional, Rimassa, Lorenza, additional, Leone, Francesco, additional, Rosati, Gerardo, additional, Santini, Daniele, additional, Giampieri, Riccardo, additional, Di Donato, Samantha, additional, Tomasello, Gianluca, additional, Silvestris, Nicola, additional, Pietrantonio, Filippo, additional, Battaglin, Francesca, additional, Avallone, Antonio, additional, Scartozzi, Mario, additional, Lutrino, Eufemia Stefania, additional, Melisi, Davide, additional, Antonuzzo, Lorenzo, additional, Pellegrino, Antonio, additional, Ferrari, Laura, additional, Bordonaro, Roberto, additional, Vivaldi, Caterina, additional, Gerratana, Lorenzo, additional, Bozzarelli, Silvia, additional, Filippi, Roberto, additional, Bilancia, Domenico, additional, Russano, Marco, additional, and Aprile, Giuseppe, additional

Published
2017
Full Text
View/download PDF

186. Clocking cancer: the circadian clock as a target in cancer therapy

Author

Battaglin, Francesca, Chan, Priscilla, Pan, Yuanzhong, Soni, Shivani, Qu, Meng, Spiller, Erin R., Castanon, Sofi, Roussos Torres, Evanthia T., Mumenthaler, Shannon M., Kay, Steve A., and Lenz, Heinz-Josef

Abstract

Disruption of the cellular pathway modulating endogenous 24-h rhythms, referred to as “the circadian clock”, has been recently proven to be associated with cancer risk, development, and progression. This pathway operates through a complex network of transcription-translation feedback loops generated by a set of interplaying proteins. The expression of core circadian clock genes is frequently dysregulated in human tumors; however, the specific effects and underlying mechanisms seem to vary depending on the cancer types and are not fully understood. In addition, specific oncogenes may differentially induce the dysregulation of the circadian clock in tumors. Pharmacological modulation of clock components has been shown to result in specific lethality in certain types of cancer cells, and thus holds great promise as a novel anti-cancer therapeutic approach. Here we present an overview of the rationale and current evidence for targeting the clock in cancer treatment.

Published
2021
Full Text
View/download PDF

187. Large-scale analysis of KMT2mutations defines a distinctive molecular subset with treatment implication in gastric cancer

Author

Wang, Jingyuan, Xiu, Joanne, Baca, Yasmine, Battaglin, Francesca, Arai, Hiroyuki, Kawanishi, Natsuko, Soni, Shivani, Zhang, Wu, Millstein, Joshua, Salhia, Bodour, Goldberg, Richard M., Philip, Philip A., Seeber, Andreas, Hwang, Jimmy J., Shields, Anthony F., Marshall, John L., Astsaturov, Igor, Craig Lockhart, A., Gatalica, Zoran, Michael Korn, W., and Lenz, Heinz-Josef

Abstract

Frequent mutations of genes in the histone-lysine N-methyltransferase 2 (KMT2) family members were identified in gastric cancers (GCs). Understanding how gene mutations of KMT2family affect cancer progression and tumor immune microenvironment may provide new treatment strategies. A total of 1245 GCs were analyzed using next-generation sequencing, whole transcriptome sequencing, immunohistochemistry (Caris Life Sciences, Phoenix, AZ). The overall mutation rate of genes in the KMT2 family was 10.6%. Compared to KMT2-wild-type GCs, genes involved in epigenetic modification, receptor tyrosine kinases/MAPK/PI3K, and DNA damage repair (DDR) pathways had higher mutation rates in KMT2-mutant GCs (p< 0.05). Significantly higher rates of high tumor mutational burden, microsatellite instability-high/mismatch-repair deficiency (dMMR), and PD-L1 positivity were observed in KMT2-mutant GCs (p< 0.01), compared to KMT2-wild-type GCs. The association between PD-L1 positivity and KMT2mutations remained significant in the proficient-MMR and microsatellite stable subgroup. Based on transcriptome data from the TCGA, cell cycle, metabolism, and interferon-α/β response pathways were significantly upregulated in KMT2-mutant GCs than in KMT2-wild-type GCs. Patients with KMT2mutation treated with immune checkpoint inhibitors had longer median overall survival compared to KMT2-wild-type patients with metastatic solid tumors (35 vs. 16 months, HR = 0.73, 95% CI: 0.62–0.87, p= 0.0003). In conclusion, this is the largest study to investigate the distinct molecular features between KMT2-mutant and KMT2-wild-type GCs to date. Our data indicate that GC patients with KMT2mutations may benefit from ICIs and drugs targeting DDR, MAPK/PI3K, metabolism, and cell cycle pathways.

Published
2021
Full Text
View/download PDF

189. Angiogenesis inhibitors and symptomatic anal ulcers in metastatic colorectal cancer patients

Author

Bergamo, Francesca, primary, Lonardi, Sara, additional, Salmaso, Beatrice, additional, Lacognata, Carmelo, additional, Battaglin, Francesca, additional, Cavallin, Francesco, additional, Saadeh, Luca, additional, Murgioni, Sabina, additional, Caruso, Antonino, additional, Aliberti, Camillo, additional, Zagonel, Vittorina, additional, Castoro, Carlo, additional, and Scarpa, Marco, additional

Published
2017
Full Text
View/download PDF

190. Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer

Author

Okazaki, Satoshi, primary, Schirripa, Marta, additional, Loupakis, Fotios, additional, Cao, Shu, additional, Zhang, Wu, additional, Yang, Dongyun, additional, Ning, Yan, additional, Berger, Martin D., additional, Miyamoto, Yuji, additional, Suenaga, Mitsukuni, additional, Iqubal, Syma, additional, Barzi, Afsaneh, additional, Cremolini, Chiara, additional, Falcone, Alfredo, additional, Battaglin, Francesca, additional, Salvatore, Lisa, additional, Borelli, Beatrice, additional, Helentjaris, Timothy G., additional, and Lenz, Heinz-Josef, additional

Published
2017
Full Text
View/download PDF

191. Prognostic and predictive role of neutrophils/lymphocytes ratio in metastatic colorectal cancer: A retrospective analysis of the TRIBE study by Gono

Author

Dell' Aquila, Emanuela, primary, Cremolini, Chiara, additional, Zeppola, Tea, additional, Lonardi, Sara, additional, Bergamo, Francesca, additional, Moretto, Roberto, additional, Stellato, Marco, additional, Marmorino, Federica, additional, Battaglin, Francesca, additional, Cortesi, Enrico, additional, Ronzoni, Monica, additional, Tomasello, Gianluca, additional, Zaniboni, Alberto, additional, Racca, Patrizia, additional, Buonadonna, Angela, additional, Allegrini, Giacomo, additional, Fea, Elena, additional, Di Donato, Samantha, additional, Chiara, Silvana, additional, Tonini, Giuseppe, additional, Falcone, Alfredo, additional, and Santini, Daniele, additional

Published
2017
Full Text
View/download PDF

192. Rechallenge with cetuximab + irinotecan in 3rd-line in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) patients with acquired resistance to 1st-line cetuximab+irinotecan: The phase II CRICKET study by GONO.

Author

Rossini, Daniele, primary, Santini, Daniele, additional, Cremolini, Chiara, additional, Salvatore, Lisa, additional, Lonardi, Sara, additional, Dell' Aquila, Emanuela, additional, Aprile, Giuseppe, additional, Loupakis, Fotios, additional, Vincenzi, Bruno, additional, Battaglin, Francesca, additional, Buoro, Vanessa, additional, Tamburini, Emiliano, additional, Basile, Deborah, additional, Corsi, Domenico, additional, Fioroni, Iacopo, additional, Masi, Gianluca, additional, Antoniotti, Carlotta, additional, Borelli, Beatrice, additional, Del Re, Marzia, additional, Tonini, Giuseppe, additional, and Falcone, Alfredo, additional

Published
2017
Full Text
View/download PDF

193. Real-world gastric cancer patients treated with at least three lines of chemotherapy: Outcomes and predictors for efficacy.

Author

Fanotto, Valentina, primary, Uccello, Mario, additional, Pecora, Irene, additional, Rimassa, Lorenza, additional, Leone, Francesco, additional, Rosati, Gerardo, additional, Santini, Daniele, additional, Giampieri, Riccardo, additional, Di Donato, Samantha, additional, Tomasello, Gianluca, additional, Silvestris, Nicola, additional, Pietrantonio, Filippo, additional, Battaglin, Francesca, additional, Avallone, Antonio, additional, Scartozzi, Mario, additional, Lutrino, Stefania, additional, Melisi, Davide, additional, Antonuzzo, Lorenzo, additional, Pellegrino, Antonio, additional, and Aprile, Giuseppe, additional

Published
2017
Full Text
View/download PDF

194. Angiogenesis inhibitor bevacizumab and symptomatic anal ulcers in metastatic colorectal cancer patients: A single center experience.

Author

Battaglin, Francesca, primary, Bergamo, Francesca, additional, Salmaso, Beatrice, additional, Murgioni, Sabina, additional, Intini, Rossana, additional, Saadeh, Luca, additional, Cavallin, Francesco, additional, Manai, Chiara, additional, Urbano, Federica, additional, Lonardi, Sara, additional, Lacognata, Carmelo, additional, Aliberti, Camillo, additional, Zagonel, Vittorina, additional, Castoro, Carlo, additional, and Scarpa, Marco, additional

Published
2017
Full Text
View/download PDF

195. Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer

Author

Pietrantonio, Filippo, primary, Vernieri, Claudio, additional, Siravegna, Giulia, additional, Mennitto, Alessia, additional, Berenato, Rosa, additional, Perrone, Federica, additional, Gloghini, Annunziata, additional, Tamborini, Elena, additional, Lonardi, Sara, additional, Morano, Federica, additional, Picciani, Benedetta, additional, Busico, Adele, additional, Volpi, Chiara Costanza, additional, Martinetti, Antonia, additional, Battaglin, Francesca, additional, Bossi, Ilaria, additional, Pellegrinelli, Alessio, additional, Milione, Massimo, additional, Cremolini, Chiara, additional, Di Bartolomeo, Maria, additional, Bardelli, Alberto, additional, and de Braud, Filippo, additional

Published
2017
Full Text
View/download PDF

196. Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world

Author

Fanotto, Valentina, primary, Cordio, Stefano, additional, Pasquini, Giulia, additional, Fontanella, Caterina, additional, Rimassa, Lorenza, additional, Leone, Francesco, additional, Rosati, Gerardo, additional, Santini, Daniele, additional, Giampieri, Riccardo, additional, Di Donato, Samantha, additional, Tomasello, Gianluca, additional, Silvestris, Nicola, additional, Pietrantonio, Filippo, additional, Battaglin, Francesca, additional, Avallone, Antonio, additional, Scartozzi, Mario, additional, Lutrino, Eufemia Stefania, additional, Melisi, Davide, additional, Antonuzzo, Lorenzo, additional, Pellegrino, Antonio, additional, Torri, Valter, additional, and Aprile, Giuseppe, additional

Published
2016
Full Text
View/download PDF

197. Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.

Author

Ryuma Tokunaga, Shu Cao, Naseem, Madiha, Jae Ho Lo, Battaglin, Francesca, Puccini, Alberto, Berger, Martin D., Soni, Shivani, Millstein, Joshua, Wu Zhang, Stintzing, Sebastian, Loupakis, Fotios, Cremolini, Chiara, Heinemann, Volker, Falcone, Alfredo, Lenz, Heinz-Josef, Tokunaga, Ryuma, Cao, Shu, Lo, Jae Ho, and Zhang, Wu

Published
2019
Full Text
View/download PDF

198. Safety and Tolerability of c-MET Inhibitors in Cancer.

Author

Puccini, Alberto, Marín-Ramos, Nagore I., Bergamo, Francesca, Schirripa, Marta, Lonardi, Sara, Lenz, Heinz-Josef, Loupakis, Fotios, and Battaglin, Francesca

Subjects
MET receptor, PROTEIN-tyrosine kinase inhibitors, HEPATOCYTE growth factor, CANCER invasiveness, CANCER treatment, DRUG efficacy, MEDICATION safety
Abstract

The role of aberrant hepatocyte growth factor receptor (c-MET, also known as tyrosine-protein kinase MET)/hepatocyte growth factor (HGF) signaling in cancer progression and invasion has been extensively studied. c-MET inhibitors have shown promising pre-clinical and early phase clinical trial anti-tumor activity in several tumor types, although results of most phase III trials with these agents have been negative. To date, two small molecule c-MET inhibitors, cabozantinib and crizotinib, have been approved by regulatory authorities for the treatment of selected cancer types, but several novel c-MET inhibitors (either monoclonal antibodies or small molecule c-MET tyrosine kinase inhibitors) and treatment combinations are currently under study in different settings. Here we provide an overview of the mechanism of action and rationale of c-MET inhibition in cancer, the efficacy of approved agents, and novel promising c-MET-inhibitors and novel targeted combination strategies under development in different cancer types, with a focus on the safety profile and tolerability of these compounds. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

200. q-Diffusion leverages the full dimensionality of gene coexpression in single-cell transcriptomics.

Author

Marmarelis, Myrl G., Littman, Russell, Battaglin, Francesca, Niedzwiecki, Donna, Venook, Alan, Ambite, Jose-Luis, Galstyan, Aram, Lenz, Heinz-Josef, and Ver Steeg, Greg

Subjects
*TRANSCRIPTOMES, *CLINICAL trials, *GENE libraries, *CYTOLOGY, *RNA sequencing, *RAS oncogenes
Abstract

Unlocking the full dimensionality of single-cell RNA sequencing data (scRNAseq) is the next frontier to a richer, fuller understanding of cell biology. We introduce q-diffusion, a framework for capturing the coexpression structure of an entire library of genes, improving on state-of-the-art analysis tools. The method is demonstrated via three case studies. In the first, q-diffusion helps gain statistical significance for differential effects on patient outcomes when analyzing the CALGB/SWOG 80405 randomized phase III clinical trial, suggesting precision guidance for the treatment of metastatic colorectal cancer. Secondly, q-diffusion is benchmarked against existing scRNAseq classification methods using an in vitro PBMC dataset, in which the proposed method discriminates IFN-γ stimulation more accurately. The same case study demonstrates improvements in unsupervised cell clustering with the recent Tabula Sapiens human atlas. Finally, a local distributional segmentation approach for spatial scRNAseq, driven by q-diffusion, yields interpretable structures of human cortical tissue. The q-diffusion method uses the full dimensionality of gene coexpression in transcriptomics and benchmarking shows improvment of scRNAseq analyses. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results